INS and type 1 diabetes mellitus: Patients with the CLEC16A T1D risk variant, rs12708716-G, have reduced expression of CLEC16A in islets and attenuated insulin secretion[16], providing further evidence that CLEC16A could control β-cell function and contribute to diabetes risk through complex interactions between resident pancreatic cells, NK cells and potentially other immune cells where CLEC16A is known to play a key role[17].